- Home
- » Tags
- » Alglucerase
Top View
- Inherited Metabolic Disorders Involving The
- Imiglucerase in the Management of Gaucher Disease Type 1 Open Access to Scientific and Medical Research DOI
- 022458Orig1s000
- Summary Plan Description
- USP Class Example Part D Eligible Drugs* Salt/Ester
- Long-Term Adverse Event Profile from Four Completed Trials of Oral Eliglustat in Adults with Gaucher Disease Type 1 M
- Extract from the Clinical Evaluation Report [2] for Taliglucerase Alfa Rpc
- (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al
- Orphan Drug Designation List
- 5.01.576 Drugs for Rare Diseases
- Genzyme Cerezyme (Imiglucerase for Injection) PROPOSED TEXT of the LABELING of the DRUG
- TITLE: Eliglustat Tartrate, Miglustat, Imiglucerase, Velaglucerase Or A
- Alglucerase Injection)
- Elelyso, INN-Taliglucerase Alfa
- Extract from the Clinical Evaluation Report for Eliglustat (As Tartrate)
- Velaglucerase Alfa in the Treatment of Gaucher Disease Type 1
- Imiglucerase in the Treatment of Gaucher Disease: a History and Perspective
- 205494Orig1s000
- Dostupnost Léčiv Pro Trávicí Trakt a Metabolická Onemocnění: Kouzlo
- ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Orphan: the Quest to Save Children with Rare Genetic Disorders
- Extract from Clinical Evaluation Report for Taliglucerase Alfa
- Erythrocytes As Carriers of Therapeutic Enzymes
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Dose-Response Relationships for Enzyme Replacement Therapy with Imiglucerase/Alglucerase in Patients with Gaucher Disease Type 1 Gregory A
- Clinicalkey Drug Monographs
- 2020 Table of Drugs
- Pharmaceutical Appendix to the Tariff Schedule 2
- Orphan Drug Designations and Approvals List As of 12‐01‐2014
- Failure of Alglucerase Infused Into Gaucher Disease Patients to Localize in Marrow Macrophages
- [Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
- Title 16. Crimes and Offenses Chapter 13
- Long-Term Velaglucerase Alfa Treatment in Children with Gaucher Disease Type 1 Naïve to Enzyme Replacement Therapy Or Previously Treated with Imiglucerase
- Binding, Internalization, and Degradation of Mannose-Terminated Glucocerebrosidase by Macrophages
- Orphan Drugs in the United States Providing Context for Use and Cost
- Enzyme Replacement Therapy for Gaucher Disease Cerezyme
- 022458Orig1s000
- Imiglucerase (Cerezyme) Reference Number: ERX.SPMN.33 Effective Date: 10/16 Coding Implications Last Review Date: 09/16 Revision Log
- Zavesca (Miglustat) PRODUCTS AFFECTED Zavesca CAPS 100MG, Package Size 18 Caps, 90 Caps
- Of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Gaucher Disease Type 1: Safety and Tolerability
- Resolution Ap (2000) 1
- Current Marketing Authorisations for Gaucher Disease
- Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
- An Analysis of Factors in the Approval of Orphan Drugs for the Rarest Diseases
- Cme Reviewarticle
- Methodik Der ATC-Klassifikation Und DDD-Festlegung Für Den Deutschen
- Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016